FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging StudyHOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the development of induced pluripotent stem cell (iPSC)-derived allogeneic neural cell therapy products, announced today that it has successfully convened an End-of-Phase 1 (EOP1) meeting with the U.S. Food and Drug Administration (FDA) recently. The two parties reached a high level of consensus on the accelerated clinical development pathway of the core product, hNPC01 Injection, for the treatment of chronic motor dysfunction due to ischemic stroke.
